Produktneuigkeiten Hier finden Sie die neuesten Produktinformationen
-
Launched Anyplex™ VanR Real-Time detection
Anyplex™ VanR Real-Time detection Simultaneous detection of vanA, vanB, and vanC geneEnterococci are the major cause of surgical-site infections and the third leading cause of urinary tract and bloodstream infections. Vancomycin is an antibiotic that is often used to treat infections caused by these Enterococci. In some instances, Enterococci become resistant to this drug and thus are called vancomycin-resistant Enterococci (VRE). Most VRE infections occur in hospitals. Vancomycin-resistant Enterococci (VRE) are now an increasingly important problem in hospitals worldwide. Both vanA and vanB genes are transferable and can spread from organism to organism. For this reason, an accurate detection is necessary in order to separate the carriers from patients. On the other hand, vanC genes are not transferable and less significant clinically, and moreover they do not require carriers to be secluded. However, the detection of vanC is still important for discrimination of VRE with acquired resistance as well as for preventing unnecessary procedures for infection management.
Feb 01, 2010｜ Anyplex™ VanR Real-time Detection
-
Launched Anyplex™ MTB/NTM Real-Time Detection
Anyplex™ MTB/NTM Real-Time Detection Identification of MTB dissociated from NTM Anyplex™ MTB/NTM Real-time Detection is designed for identification of Mycobacterium tuberculosis (MTB) dissociated from non-tuberculosis mycobacteria (NTM) in various specimens such as sputum, aseptic fluids (pleural fluid, blood, bone marrow aspiration), bronchial washing, fresh tissue, culture specimens (solid and liquid culture), urine and stool. Although culture is a standard method to diagnose active tuberculosis, it is difficult to discriminate MTB from NTM by culture due to their similar colony morphologies. Anyplex™ MTB/NTM Real-time Detection is a DNA-based testing product which can accurately discriminate MTB from NTM. Therefore, this product enables a proper treatment of the patients by determining MTB from NTM infection. NOT AVAILABLE IN US
Jan 02, 2010｜ Anyplex™ MTB/NTM Real-time Detection
-
Launched Magicplex™ VanR Real-Time Detection
Magicplex™ VanR Real-Time Detection Simultaneous detection of vanA, vanB, and vanC genes The importance of testing for VRE VRE (vancomycin-resistant enterococci) are an important category of opportunistic pathogenic bacteria, the occurrence of which has risen in frequency worldwide with the increase in the use of vancomycin. As most VRE display resistance to multiple drugs, they are difficult to treat. In addition, their resistant characteristics may be passed on to other opportunistic pathogenic bacteria, such as the Staphylococcus aureus, which can be highly problematic. Therefore, in order to prevent the spread of VRE in the hospital, conducting a test for VRE quickly and accurately is essential. Vancomycin resistance genotyping vanA and vanB genes are transferable and can spread from organism to organism. So, accurate detection is required in order to separate the carriers from patients. vanC genes are not transferable and have little clinical importance, and do not require the carrier to be secluded. The detection of vanC is necessary for discriminating VRE with acquired resistance, and for preventing unnecessary infection management procedures. VRE diagnostic methods Disk diffusion test and automated systems, such as the Vitek system or the Microscan, have high accuracy and reliability. These methods, however, are able to only test for phenotypes, and cannot determine the exact genotypes. Moreover, as there have been reports of VRE which has incongruent genotypes against its phenotypes, a molecular biological test is necessary in order to identify resistant genotypes. NOT AVAILABLE IN US
Jan 01, 2010｜ Magicplex VanR Real-Time Detection
-
Obtained CE-IVD marking for Allplex™ Bacterial Vaginosis Assay
Allplex™ Bacterial Vaginosis Assay simultaneously detects 7 bacteria (G. vaginalis, A. vaginae, Megasphaera type 1, BV-associated bacteria 2, Mobiluncus spp., B. fragilis, Lactobacillus spp.) associated with vaginosis. It provides quantitative information of 3 major bacteria (G. vaginalis, A. vaginae, Lactobacillus spp.). Based on Seegene’s proprietary MuDT™ technology, this assay makes it possible to report individual Ct value of multiple bacteria in a single channel. The CE-IVD mark will allow more opportunities for Seegene to market and sell within the European Union. NOT AVAILABLE IN U.S.
Dec 15, 2009｜ Allplex™ Bacterial Vaginosis Assay
-
Launched Anyplex™ FluA 3 Real-time Subtyping
Anyplex™ FluA 3 Real-time SubtypingAnyplex™ FluA 3 Real-time Subtyping enables simultaneous discrimination of 2009 pandemic H1, seasonal influenza A virus (H1) and seasonal influenza A virus (H3) by One-step Multiplex Real-time RT-PCR. NOT AVAILABLE IN USAnyplex™ FluA 3 Real-time Subtyping enables simultaneous discrimination of 2009 pandemic H1, seasonal influenza A virus (H1), seasonal influenza A virus (H3) by One-step Multiplex Real-time RT-PCR from nasopharyngeal swabs, nasopharyngeal aspirates, and bronchoalveolar lavage.
Dec 01, 2009｜ Anyplex™ FluA 3 Real-time Subtyping
-
Launched Anyplex™ FluA 2 Real-time Subtyping
Anyplex™ FluA 2 Real-time Subtyping Anyplex™ FluA 2 Real-time Subtyping enables simultaneous discrimination of influenza A virus (H1) and influenza A virus (H3) by One-step Multiplex Real-time RT-PCR. Anyplex™ FluA 2 Real-time Subtyping enables simultaneous discrimination of influenza A virus (H1) and influenza A virus (H3) by One-step Multiplex Real-time RT-PCR from nasopharyngeal swabs, nasopharyngeal aspirates, and bronchoalveolar lavage. NOT AVAILABLE IN US
Dec 01, 2009｜ Anyplex™ FluA 2 Real-time Subtyping
-
Launched Anyplex™ FluA/New H1N1 Real-Time Detection
Anyplex™ FluA/New H1N1 Real-time Detection Anyplex™ FluA/New H1N1 Real-time Detection enables simultaneous detection of 2009 pandemic H1 and influenza A virus. Anyplex™ FluA/New H1N1 Real-time Detection enables simultaneous detection of 2009 pandemic H1 and influenza A virus from nasopharyngeal swabs, nasopharyngeal aspirates, and bronchoalveolar lavage in a single reaction. NOT AVAILABLE IN US
Nov 01, 2009｜ Anyplex™ FluA/New H1N1 Real-Time Detection
-
Received Approval from Health Canada for Seepelx® RV5 ACE Screening...
Seeplex® RV5 ACE Screening Rapid screening of most prevalent respiratory viruses Seeplex® RV5 ACE Screening has been given a Medical Device License by Health Canada. The licenses will enhance the opportunity in the Canadian market.NOT AVAILABLE IN US Seeplex® RV 12 ACE Detection Simultaneously detection 12 major respiratory viruses Seeplex® RV 12 ACE Detection has been given a Medical Device License by Health Canada. The licenses will enhance the opportunity in the Canadian market.NOT AVAILABLE IN US
Nov 03, 2008｜ Seeplex® RV12 ACE Detection , Seeplex® RV5 ACE Screening
